Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?

General Info

Geography

Netherlands (NLD)

Time period covered

January, 2001 - December, 2005

Data type

Scientific literature

Keywords

Chemotherapy, Health care costs, Multiple myeloma

Citation

Authors

Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, Uyl-de Groot CA

Journal

Value Health

Pages

245-53

Publication year

2014

Suggested citation

Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, Uyl-de Groot CA. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib?. Value Health. 2014; 17(2): 245-53.